କାବୋଜାଣ୍ଟିନିବ

କାବୋଜାଣ୍ଟିନିବ
Clinical data
Pronunciationka" boe zan' ti nib[୨]
Trade namesCometriq, Cabometyx, others
SynonymsXL184, BMS907351
AHFS/Drugs.commonograph
MedlinePlusa613015
data
Pregnancy
category
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Protein binding≥99.7%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life110 hours
ExcretionFeces (54%), urine (27%)
Identifiers
  • N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
ECHA InfoCard100.221.147 Edit this at Wikidata
Chemical and physical data
FormulaC28H24FN3O5
Molar mass୫୦୧.୫୧ g·mol−1
3D model (JSmol)
  • O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC(C=C3)=CC=C3OC4=C(C=C(OC)C(OC)=C5)C5=NC=C4
  • InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
  • Key:ONIQOQHATWINJY-UHFFFAOYSA-N

କାବୋଜାଣ୍ଟିନିବ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବିକ୍ରୟ ନାମ କୋମେଟ୍ରିକ (Cometriq) ଏବଂ କାବୋମରଟିକ୍ସ (Cabometyx), ଏକ ଔଷଧ ଯାହା ମେଡୁଲାରୀ ଥାଇରଏଡ କର୍କଟ, ବୃକ୍‌କ କୋଷ କର୍କଟ ଏବଂ ହେପାଟୋସେଲୁଲାର୍ କର୍କଟ ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । [୯] [୧୦] ଏହା ଉନ୍ନତ ରୋଗ କିମ୍ବା ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହୋଇଥିବା କ୍ଷେତ୍ରରେ ବ୍ୟବହୃତ ହୁଏ । [୧୧] ଏହା ପାଟିରେ ଦିଆଯାଏ | [୧୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ଥକାପଣ, ଉଚ୍ଚ ରକ୍ତଚାପ, ବାନ୍ତି, ଏବଂ ଓଜନ ହ୍ରାସ ହୁଏ । [୧୦] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ, ଫିଷ୍ଟୁଲା, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, ଯକୃତ ସମସ୍ୟା ଏବଂ ରିଭର୍ସିବଲ୍ ପୋଷ୍ଟୋରିଅର୍ ଲ୍ୟୁକୋଏନସେଫାଲୋପାଥି ସିଣ୍ଡ୍ରୋମ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ। [୧୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । [୧୧] ଏହା ଏମଇଟ, (MET), ଭିଇଜିଏଫଆର (VEGFR), ଏବଂ ଏଏକ୍ସଏଲ (AXL)ମାନଙ୍କର ଟାଇରୋସିନ୍ କାଇନେଜ ଇନହିବିଟର । [୧୧]

୨୦୧୨ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୪ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ କାବୋଜାଣ୍ଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା [୯][୧୦] ୨୦୨୧ରେ ଯୁକ୍ତରାଜ୍ୟରେ ୬୦ମିଗ୍ରା ଔଷଧର ଏକ ମାସର ମୂଲ୍ୟ ୫୧୫୦ ପାଉଣ୍ଡ ଥିଲା । [୧୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୨,୬୦୦ ଡଲାର ଅଟେ । [୧୩]

ଆଧାର

[ସମ୍ପାଦନା]
  1. ↑ "Cabozantinib Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 3 December 2020. Retrieved 23 September 2020.
  2. ↑ "Cabozantinib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 11 January 2022. Retrieved 29 December 2021.
  3. ↑ "Cometriq EPAR". European Medicines Agency (EMA). Archived from the original on 2 October 2018. Retrieved 23 September 2020.
  4. ↑ "Cabometyx EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 23 September 2020.
  5. ↑ "Cabozantinib tablet (Cabometyx) UK Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 2019-06-23. Retrieved 2021-10-05.
  6. ↑ "Cabozantinib capsule (Cometriq) UK Summary of Product Characteristics (SPC) - (eMC)". UK Electronic Medicines Compendium. November 2016. Archived from the original on 2019-06-23. Retrieved 2021-10-05.
  7. ↑ "Cabometyx- cabozantinib tablet". DailyMed. 21 July 2020. Archived from the original on 29 October 2020. Retrieved 23 September 2020.
  8. ↑ "Cometriq- cabozantinib kit Cometriq- cabozantinib capsule". DailyMed. 11 February 2020. Archived from the original on 29 October 2020. Retrieved 23 September 2020.
  9. ↑ ୯.୦ ୯.୧ "Cometriq EPAR". European Medicines Agency (EMA). Archived from the original on 2 October 2018. Retrieved 23 September 2020.
  10. ↑ ୧୦.୦ ୧୦.୧ ୧୦.୨ "DailyMed - CABOMETYX- cabozantinib tablet". dailymed.nlm.nih.gov. Archived from the original on 29 October 2020. Retrieved 29 December 2021.
  11. ↑ ୧୧.୦ ୧୧.୧ ୧୧.୨ ୧୧.୩ ୧୧.୪ "DailyMed - CABOMETYX- cabozantinib tablet". dailymed.nlm.nih.gov. Archived from the original on 29 October 2020. Retrieved 29 December 2021.
  12. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1017. ISBN 978-0857114105.
  13. ↑ "Cabometyx Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 29 December 2021.